Cargando…

The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma

Purpose: The systemic inflammation response index (SIRI), based on peripheral neutrophil, monocyte, and lymphocyte counts, was recently emerged and used as a novel tool in predicting prognosis in different types of cancer. Our aim was to investigate the clinical significance of preoperative SIRI in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shuo, Xu, Huaxiang, Wang, Wenquan, Gao, Heli, Li, Hao, Zhang, Shirong, Xu, Jinzhi, Zhang, Wuhu, Xu, Shuaishuai, Li, Tianjiao, Ni, Quanxing, Yu, Xianjun, Wu, Chuntao, Liu, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489619/ https://www.ncbi.nlm.nih.gov/pubmed/31114368 http://dx.doi.org/10.2147/CMAR.S197911

Ejemplares similares

Prognostic value of γ‐glutamyltransferase‐to‐albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery
por: Li, Shuo, et al.
Publicado: (2019)

Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma
por: Li, Tianjiao, et al.
Publicado: (2019)

The role of collagen in cancer: from bench to bedside
por: Xu, Shuaishuai, et al.
Publicado: (2019)

Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21
por: Lin, Xuan, et al.
Publicado: (2021)

Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer
por: Ye, Longyun, et al.
Publicado: (2022)

High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma
por: Gong, Yitao, et al.
Publicado: (2021)

Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2020)

Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma
por: Li, Xiaojie, et al.
Publicado: (2020)

A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma
por: Zhang, Yiyin, et al.
Publicado: (2019)

Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2022)

Application of “Papillary-Like Main Pancreatic Duct Invaginated” Pancreaticojejunostomy for Normal Soft Pancreas Cases
por: Zhang, Bo, et al.
Publicado: (2013)

Prognostic impact of Ki‐67 proliferative index in resectable pancreatic ductal adenocarcinoma
por: Pergolini, I., et al.
Publicado: (2019)

Cachexia index as a prognostic predictor after resection of pancreatic ductal adenocarcinoma
por: Shimagaki, Tomonari, et al.
Publicado: (2023)

Precise and efficient silencing of mutant Kras(G12D) by CRISPR-CasRx controls pancreatic cancer progression
por: Jiang, Wang, et al.
Publicado: (2020)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Intra-tumoral infiltration of adipocyte facilitates the activation of antitumor immune response in pancreatic ductal adenocarcinoma
por: Liu, Xiaomeng, et al.
Publicado: (2022)

The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection
por: Gruber, Elisabeth S., et al.
Publicado: (2020)

The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma
por: Wu, Zijian, et al.
Publicado: (2022)

Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
por: Cao, Ying-Ying, et al.
Publicado: (2023)

Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection
por: Sugawara, Toshitaka, et al.
Publicado: (2021)

A Simple Model Established by Blood Markers Predicting Overall Survival After Radical Resection of Pancreatic Ductal Adenocarcinoma
por: Zhang, Li-xiang, et al.
Publicado: (2020)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Cbl-b predicts postoperative survival in patients with resectable pancreatic ductal adenocarcinoma
por: Dong, Qian, et al.
Publicado: (2017)

A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma
por: Zhu, Lingyu, et al.
Publicado: (2023)

Ploidy and DNA index as prognostic factors in resected pancreatic ductal adenocarcinoma – a review of the literature
por: Durlik, Marek, et al.
Publicado: (2014)

A Novel Nomogram to Predict Survival in Patients With Recurrence of Pancreatic Ductal Adenocarcinoma After Radical Resection
por: He, Chaobin, et al.
Publicado: (2020)

Acid sphingomyelinase expression is associated with survival in resectable pancreatic ductal adenocarcinoma
por: Wilson, Gregory C., et al.
Publicado: (2023)

Preoperative recurrence prediction in pancreatic ductal adenocarcinoma after radical resection using radiomics of diagnostic computed tomography
por: Li, Xiawei, et al.
Publicado: (2021)

A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection
por: He, Chaobin, et al.
Publicado: (2019)

Methylation of CALCA and CALCB in Pancreatic Ductal Adenocarcinoma
por: Gao, Feng, et al.
Publicado: (2021)

Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study
por: Pu, Ning, et al.
Publicado: (2023)

Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma
por: Ormanns, Steffen, et al.
Publicado: (2015)

Pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head with venous resection
por: Flis, Vojko, et al.
Publicado: (2016)

Contemporary management of borderline resectable pancreatic ductal adenocarcinoma
por: Lekka, Kyriaki, et al.
Publicado: (2019)

Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Bonds, Morgan, et al.
Publicado: (2019)

Coexpression of EGFR and CXCR4 Predicts Poor Prognosis in Resected Pancreatic Ductal Adenocarcinoma
por: Wu, Huanwen, et al.
Publicado: (2015)

Alkaline Phosphatase-To-Albumin Ratio as a Prognostic Indicator in Pancreatic Ductal Adenocarcinoma after Curative Resection
por: Pu, Ning, et al.
Publicado: (2017)

Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Resectable pancreatic ductal adenocarcinoma: association between preoperative CT texture features and metastatic nodal involvement
por: Fang, Wei Huan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kn7kbp4akvkljc1obtrqorch44